Business
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services,
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida.NeoGenomics, alongside collaborators, will present new data demonstrating the broad portfolio of services and available validated assays focused on tumor biology, including the use of RaDaR®, a personalized, highly-sensitive liquid biopsy sequencing test for the detection of minimal residual disease (MRD) and recurrence.\"We are especially excited to share data on RaDaR, comparing the performance of NeoGenomics' proprietary technology to other MRD tests on the market,\" said Dr. Shashikant Kulkarni, MS, Ph.D., MBA, FACMG, Chief Scientific Officer of NeoGenomics. \"These data highlight our deep expertise in NGS profiling and our commitment to innovation in cancer monitoring to better service cancer patients and their providers.\"Details of the poster presentations are outlined below, and further details can be found at AACR.org.Title: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Abstract #3382.Monday, April 17, 1:30pm-5:00pm.Title: Single-tube NGS profiling allows identification of molecular signature in ALL patients. Abstract #219. Sunday, April 16, 1:30pm-5:00pm.Title: Landscape of known and novel myeloid neoplasia fusions identified by a multimodal comprehensive genomic profiling test in 789 patients. Abstract #1401. Monday, April 17, 9:00am-12:30pm.Title: ctDNA dynamics in early stage node negative lung cancers. Abstract #3387.Monday, April 17, 1:30pm-5:00pm.Title: Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies.Abstract #4294.Tuesday, April 18, 9:00am-12:30pm.Title: Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence.Abstract #4639.Tuesday, April 18, 1:30pm-5:00pm.Title: Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyxTM. Abstract #4696.Tuesday, April 18, 1:30pm-5:00pm.Title: Comprehensive analysis of natural killer cell-ass...